Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 154, Issue -, Pages 79-101Publisher
ELSEVIER
DOI: 10.1016/j.addr.2020.06.017
Keywords
Lipid nanoparticle; Liver targeting; Liposome; Solid lipid nanoparticles; Niosome; Liver fibrosis; Hepatitis; Hepatocellular carcinoma
Categories
Funding
- Canadian Institutes of Health Research (CIHR) [PJT-148610, PJT-168861]
- Natural Science and Engineering Research Council in Canada (NSERC) [RGPIN-2017-03787]
- Canada Foundation for Innovation (CFI) [35816]
- Mitacs Accelerate grant - Precision Nanosystems Inc. [IT13402]
- Canadian Cancer Society [706231]
- Michael Smith Foundation for Health Research [18711]
- Faculty of Pharmaceutical Sciences at the University of British Columbia (UBC)
- Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [423802991]
- UBC
- National Organization for Rare Disorders -the Appendix Cancer/Pseudomyxoma Peritonei Research Foundation [18004]
Ask authors/readers for more resources
Liver diseases such as hepatitis, cirrhosis, and hepatocellular carcinoma are global health problems accounting for approximately 800 million cases and over 2 million deaths per year worldwide. Major drawbacks of standard pharmacological therapies are the inability to deliver a sufficient concentration of a therapeutic agent to the diseased liver, and nonspecific drug delivery leading to undesirable systemic side effects. Additionally, depending on the specific liver disease, drug delivery to a subset of liver cells is required. In recent years, lipid nanoparticles have been developed to passively and actively target drugs to the liver. The success of this approach has been highlighted by the FDA-approval of the first liver-targeting lipid nanoparticle, ONPATTRO, in 2018 and many other promising candidate technologies are expected to follow. This review summarizes recent developments of various lipid-based liver-targeting technologies, namely solid-lipid nanoparticles, liposomes, niosomes and micelles, and discusses the challenges and future perspectives in this field. (C) 2020 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available